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httpFeasibility and safety of endovascular treatment for
chronic cerebrospinal venous insufﬁciency in
patients with multiple sclerosis
Tommaso Lupattelli, MD,a Giovanni Bellagamba, MD,a Elena Righi, MD,b Vincenzo Di Donna, MD,a
Isac Flaishman, MD,a Rita Fazioli, MD,a Francesco Garaci, MD,c and Paolo Onorati, MD,a Rome and Reggio
Emilia, Italy
Objective: Chronic cerebrospinal venous insufﬁciency (CCSVI) is a recently discovered syndrome mainly due to stenoses of
internal jugular (IJV) and/or azygos (AZ) veins. The present study retrospectively evaluates the feasibility and safety of
endovascular treatment for CCSVI in a cohort of patients with multiple sclerosis (MS).
Methods: From September 2010 to October 2012, 1202 consecutive patients were admitted to undergo phlebograpy 6
endovascular treatment for CCSVI. All the patients had previously been found positive at color Doppler sonography
(CDS) for at least two Zamboni criteria for CCSVI and had a neurologist-conﬁrmed diagnosis of MS. Only symptomatic
MS were considered for treatment. Percutaneous transluminal angioplasty was carried out as an outpatient procedure at
two different institutes. Primary procedures, regarded as the ﬁrst balloon angioplasty ever performed for CCSVI, and
secondary (reintervention) procedures, regarded as interventions performed after venous disease recurrence, were carried
out in 86.5% (1037 of 1199) and 13.5% (162 of 1199) of patients, respectively. Procedural success and complications
within 30 days were recorded.
Results: Phlebography followed by endovascular recanalization was carried out in 1999 patients consisting of 1219
interventions. Balloon angioplasty alone was performed in 1205 out of 1219 (98.9%) procedures, whereas additional
stent placement was required in the remaining 14 procedures (1.1%) following unsuccessful attempts at AZ dilatation. No
stents were ever implanted in the IJV. The feasibility rate was as high as 99.2% (1209 interventions). Major complications
included one (0.1%) AZ rupture occurring during balloon dilatation and requiring blood transfusion, one (0.1%) severe
bleeding in the groin requiring open surgery, two (0.2%) surgical openings of the common femoral vein to remove
balloon fragments, and three (0.2%) left IJV thromboses. The overall major and minor complication rates at 30 days were
0.6% and 2.5%, respectively.
Conclusions: Endovascular treatment for CCSVI appears feasible and safe. However, a proper learning curve can
dramatically lower the rate of adverse events. In our experience, the vast majority of complications occurred in the ﬁrst
400 cases performed. (J Vasc Surg 2013;58:1609-18.)Multiple sclerosis (MS) is a chronic and debilitating
disease of the central nervous system characterized by the
presence of scattered demyelinization plaques in the brain
and/or the spinalcord.1,2 Recently, the possibility has
been raised that MS is associated with a chronic cerebro-
spinal venous insufﬁciency (CCSVI), a syndrome character-
ized by stenoses or obstruction of the internal jugular
vein (IJV), brachiocephalic veins, azygos vein (AZ), and
others.3-7 Venous abnormalities can be present in several
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pathologies, different imaging modalities such as Doppler
sonography (in the form of duplex scanning), magnetic reso-
nance venography, or selective phlebography have been
used, with venous disease correspondence among these tools
being controversial in many cases.8,9 Zamboni et al, using
extracranial and transcranial sonography, established ﬁve
ultrasound venous hemodynamic criteria that were able to
distinguish MS patients from controls with 100% sensitivity
and speciﬁcity.10 A high prevalence of obstructive lesions has
been found by some groups of MS patients compared with
a low prevalence in healthy controls.11-14 On the contrary,
prevalence of such venous abnormalities has been reported
to be dramatically lower in other studies.15-20 However,
this variability could be the result of differences in technique,
training, experience, or criteria used.21,22 To ensure a high
reproducibility and accuracy between centers, recommenda-
tions for a protocol for duplex scanning has been recently
published by the Intersociety Committee of the Consensus
Conference on Practical Guidelines for the investigation
and screening of CCSVI.23
Angioplasty is the treatment of choice for lesions
producing venous disease. Nowadays, a few reports have
been reported on endovascular treatment of CCSVI1609
Table I. Color duplex sonography criteria for CCSVI
according to Zamboni et al23
CCSVI criteria
1. Reﬂux in the IJV and/or VV.
2. Reﬂux in the intracranial veins.
3. High-resolution B-mode: evidence of IJV stenosis and/or
other B-mode anomalies.
4. Absence of ﬂow in the IJV and/or VV.
5. CSA sitting > supine in the IJV.
CCSVI, Chronic cerebrospinal venous insufﬁciency; CSA, cross-sectional
area; IJV, internal jugular vein; VV, vertebral vein.
Table II. Study population
Male 547 (45.5)
Female 655 (54.5)
Age, years 35 (18-78)
MS duration 11.3 (0.5-43)
MS form
RR 584 (48.6)
SP 431 (35.9)
PP 112 (9.3)
Unknown 75 (6.2)
PP, Primary progressive; RR, relapsing remitting; SP, secondary progressive.
Data are presented as number (%) or mean (range).
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1610 Lupattelli et al December 2013patients with MS.23-28 The aim of the present study is to
retrospectively evaluate the feasibility and safety of phle-
bography and endovascular treatment for CCSVI in
a cohort of patients with MS.
METHODS
Between September 2010 and October 2012, a total of
1202 consecutive patients were admitted to undergo
phlebography 6 endovascular treatment for CCSVI. Feasi-
bility and safety of percutaneous transluminal angioplasty
were retrospectively evaluated. All patients were previously
diagnosed with CCSVI at color Doppler sonography
(CDS) according to Zamboni score10 and also had
a neurologist-conﬁrmed diagnosis of MS.29 Only symp-
tomatic MS were considered for treatment. The indication
for venography and subsequent endovascular treatment
was the presence of at least two out of ﬁve parameters of
the Zamboni score (Table I).23 Before the intervention,
all participants completed questionnaires or brief interviews
assessing medical history, medication use, parental psycho-
pathology, demographics, psychiatric symptoms, alcohol
and drug use, and cognitive status. The Mini Mental State
Examination was performed to globally test basic cognitive
functions.30 The Kurtzke Expanded Disability Status Scale
(EDSS) was performed in order to assess disability in MS
patients.31 The characteristics of the study population are
summarized in Table II.
The study received institutional review board approval,
and all participants gave their informed consent. All
patients were treated in an outpatient basis by a single
team of neurologists and vascular surgeons (Brain Flow
Team). All interventions were performed at two different
institutes by the same physician (T.L). In order to facilitate
selective study of the left ascending lumbar veins, a tributary
of the left common iliac vein, left groin, was preferred,
when possible, and an 8- or 10F, 12-cm-long sheath (Ter-
umo Medical Corporation, Elkton, Md) was introduced
under local anesthesia in the common femoral vein.
Venous puncture was carried out with a standard Seldinger
technique. CDS guidance at the time of vein puncture was
not used routinely but for difﬁcult accesses only (ie, pres-
ence of scars at the groin, obesity, etc). Patients were
administered either oral sedation with bromazepam (Bro-
mazepam; Mylan Generics, Milan, Italy) or intravenous
conscious sedation with midazolam hydrochloride (Mida-
zolam; Mylan Generics) and were continuously monitored
for heart and oxygen saturation. All patients received intra-
venous hydration 3 hours before, during, and immediately
after the procedure.
A 6F, 100-cm-long, multipurpose catheter (Cordis Co,
Miami, Fla) was selected ﬁrst to cannulate both IJVs and
left ascending lumbar veins. The multipurpose catheter
was also used for the AZ; in those cases where catheteriza-
tion of the AZ proved difﬁcult with the multipurpose cath-
eter, a 5F Cobra C1, 100 cm long (Cordis Co) was
preferred. Finally, in some patients, selective study of the
left IJV was achieved using a 6F, 100-cm-long right coro-
nary catheter (Cordis Co).Phlebography was carried out at different levels in the
IJV in every patient. Speciﬁcally, 5 mL of diluted iodine
contrast (Visipaque; Amersham Health AS, Oslo, Norway)
was injected manually with the tip of the catheter placed 10
cm above the IJV outlet (J2 level) as well as 8 to 10 cm
above it (J3 level).10 Antero-posterior and ipsilateral ante-
rior oblique views were obtained for both IJVs in all
patients. Two views (left anterior oblique at 30 degrees
and lateral) were used to visualize the AZ. Angioplasty
was carried out at the same time of phlebography. Prior
to balloon dilatation, the patients were given unfractio-
nated heparin (70 U/kg). A stenosis greater than 50%
was considered the threshold for balloon dilatation.
However, a luminal diameter reduction less than 50% in
patients with a malformed valve, membrane, or septum at
the vein outlet was also treated when associated with difﬁ-
culty passing of the guidewire through the ostium and/or
with ﬂow abnormality such as reﬂux or stasis of the contrast
medium. Type and number of vessels treated in the study
population are reported in Table III. Stenoses and occlu-
sions were treated using high-pressure balloons (Conquest
PTA Dilatation Catheter, Atlas PTA Balloon Dilatation
Catheter; Bard Peripheral Vascular, Tempe, Ariz) and/or
standard (low-pressure) balloons (Admiral XtremeTM;
Invatec, Bethelehem, Pa) either in the IJV and AZ.
Balloons, chosen depending on diameter and characteris-
tics of the vein lesion, were oversized approximately 20%
more than the target vessel size (Fig 1). Standard balloons
were selected ﬁrst to treat stenoses in the AZ, preferring
Table III. Type and number of vessels treated in the
study population
Type of intervention
Patients,
No. (%)
Procedures,
No. (%)
Endovascular treatment 1199 1219
Angioplasty 1185 (98) 1205 (98.9)
Angioplasty þ stenting 14 (0.2) 14 (0.2)
Endovascular treatment of the
right IJV
1140 (95) 1154 (94.7)
Endovascular treatment of the
left IJV
1145 (95.5) 1158 (95)
Endovascular treatment of the AZ 935 (78) 947 (77.7)
Endovascular treatment of left
anonimous vein
125 (10.4) 127 (10.4)
Endovascular treatment of left
iliac vein
24 (2) 24 (2)
AZ, Azygos vein; IJV, internal jugular vein.
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suboptimal dilatation only. High-pressure balloons were
always chosen ﬁrst for IJV angioplasty. At the beginning
of our experience where high-pressure balloons were not
still available in the market, two ordinary balloons placed
at the outlet of the IJV were inﬂated simultaneously (kiss-
ing balloon technique; Fig 2). This relatively complex
maneuver was made with the aim of achieving stronger
dilatations at the vein outlet, which is particularly resistant
to balloon opening, when standard balloon dilatation was
suboptimal. Immediate recoil, evidence of twisting, and/
or ﬂow-limiting dissection in the IJV was treated with
repeat angioplasty by means of prolonged balloon dilata-
tions (5 minutes each). Angioplasty was terminated once
all detectable lesions in the three target veins (left and right
IJVs and AZ) were treated successfully or after three
consecutive failing attempts at meliorating the blood
ﬂow through the injured vessel. Stent placement was
carried out following inadequate response to previous
attempts at balloon angioplasty only. In all patients, self-
expandable bare stents (Protégé, EverFlex; eV3, Plymouth,
Minn) were preferred to balloon-expandable ones.
Manual pressure on the groin was applied for
a minimum of 10 minutes in all patients following removal
of the introducer sheath. Patients were then observed and
monitored in the recovery room for 30 minutes by a nurse.
Afterward, they were sent back to the ward with the
recommendation to keep very still in the bed for at least
2 hours. After a further 2 hours, the patients were allowed
to ambulate under strict observation and to leave the
hospital if they were clinically stable without any abnormal-
ities of their vital signs. Recommendation about staying in
a local hotel for the following 12 hours was made to all
patients. The following morning, most of the patients
underwent CDS of the neck veins. General conditions
and punctured groin were also carefully evaluated.
Postoperative antithrombotic prophylaxis was sched-
uled as follows: 4000 U of low-molecular-weight heparin
every 12 hours for 15 days (it was prolonged to 40 days
after the ﬁrst 112 cases); 100 mg of mesoglycan (Prisma;Mediolanum Farmaceutici, Milan, Italy) every 12
hours þ 100 mg of aspirin daily for the following 3
months; and ﬁnally, aspirin 100 mg daily for the following
6 months.
Patients in whom a stent was implanted received
warfarin for the ﬁrst 6 months with the recommendation
to keep the international normalized ratio between 2 and
3, then aspirin 100 mg þ 75 mg clopidogrel (Plavix; Bristol
Meyers Squibb, New York, NY) daily for the following
6 months, and ﬁnally, 100 mg of aspirin, indeﬁnitely.
The patients were seen at our center or alternatively were
contacted by phone or by e-mail at 7 and 30 days from
the procedure. In case of procedure-related problems, the
patients were invited to contact the hospital at any time.
All of the patients were scheduled to have both clinical
and neurological evaluation as well as CDS of the neck
veins at 2, 6, 12, and 18 months at our center.
Study end points and deﬁnition. The primary end
point was the combined number of complications at 30
days after the endovascular treatment. Procedural success
and technical success were measured as additional primary
end points. Procedural success was deﬁned as capability of
performing selective catheterization of the three target
vessels, followed, if necessary, by their balloon dilatation,
whereas technical success was regarded as achievement of
normal venous return in the three target vessels. Failure
to perform the procedure, regardless of whether the
outcome was presence or absence of a complication, was
deﬁned as the inability to gain access with the introducer
sheath in the vein circulation, to engage all target vessels
with the diagnostic catheter, or to perform, whenever indi-
cated, target vessels balloon dilatation. Failure to achieve
normal venous return, regardless of whether the outcome
was presence or absence of a complication, was deﬁned as
persistence in $1 target vessel or $1 of the following
conditions: (1) occlusion or residual stenosis >50%; (2)
reﬂux or stasis of contrast medium; (3) difﬁculty passing
of the guidewire through the target vessel.
The secondary end point was the combined number of
minor complications during the ﬁrst 30 days after the
endovascular treatment. Transient chest pain, neck pain,
and/or headache were regarded as typical symptoms after
the procedure and were not registered as adverse events.
RESULTS
Stenosis >50% and/or other venous problems such as
ﬂow abnormality or difﬁculty passing of the guidewire with
evidence of a vessel narrowing <50% were seen in 85.7%
and 16.3% of the right IJV and 85.3% and 16.9% of the
left IJV, respectively. No evidence of any disease was regis-
tered in 5% and 4.5% of the right and left IJV, respectively.
Signiﬁcant disease of the AZ, regarded as evidence of
stenosis >50% and/or other venous pathology with a vessel
stenosis <50% was registered in 935 patients (78%).
Venography followed by endovascular recanalization
was carried out in 1994 patients in 1214 procedures. In
ﬁve additional patients (ﬁve procedures), the decision to
carry out the interventional treatment was solely taken after
Fig 1. Right internal jugular vein (IJV) balloon angioplasty at the vein outlet (a). No evidence of collateral vessels after
complete reopening of the vein (b). Narrowing of the left IJV at the level of the ostium (c). Angioplasty with a standard
balloon proved ineffective due to the presence of a highly resistant stenosis (d). The standard balloon was changed for
a high-pressure one that allowed full dilation of the vein lesion (e and f). Right IJV stenosis/occlusion; balloon
dilatation (g) with subsequent signiﬁcant improvement of the vein outﬂow (h).
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CDS. Three patients (three procedures) were not treated
endovascularly because no signiﬁcant disease in at least
one IJV was seen at phlebography, despite evidence of
CCSVI at CDS. Therefore, the endovascular treatment
was performed in a total of 1199 (99.8%) patients consist-
ing of 1219 (99.8%) procedures.
Balloon angioplasty alone was carried out in 1185
(98.8%) patients and in 1205 (98.9%) procedures, whereas
additional stent placement was required in the remaining
14 patients (1.2%) in 14 interventions (1.1%) following
unsuccessful attempts at AZ dilatation. No stents were
ever implanted in the IJV.23 Primary procedures, regardedas the ﬁrst balloon angioplasty ever performed for CCSVI,
and secondary (reintervention) procedures, regarded as
interventions performed after a venous disease recurrence,
were carried out in 86.5% (1037 of 1199) and 13.5%
(162 of 1199) of patients, respectively. Speciﬁcally, 1.7%
(20) of patients who underwent reinterventions had been
previously treated at our institute, whereas 11.8% (142)
were treated elsewhere. Secondary procedures were all
carried out after at least 6 months from the previous endo-
vascular intervention. All 1199 patients underwent balloon
angioplasty of one or more target vessels and at least two
balloons were employed (mean, 2.8 balloons; range, 2-9
balloons) in every case. Standard balloons of 8 to 12 mm
Fig 2. Left internal jugular vein (IJV) narrowing at the vein outlet. A large collateral vessel draining at the junction
between the subclavian and the anonymous veins is also seen (a). Balloon angioplasty with the kissing-balloon tech-
nique. Following dilatation of both balloons (b), complete reopening of the vein as well as disappearance of the large
collateral vein is seen (c).
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in the mid (J2) and distal (J3) portion of the IJV, whereas
high-pressure balloons of 10 to 26 mm in diameter and 20
to 40 mm in length were used more proximally, mostly at
the vein outlet (J1). Standard balloons ranging from 5 to
12 mm in diameter and 20 to 60 mm in length and/or
high-pressure balloons ranging from 10 to 14 mm in diam-
eter and 20 to 40 mm in length were chosen for the treat-
ment of the AZ. Standard balloons were selected ﬁrst to
treat stenoses in the AZ, reserving the use of the high-
pressure ones solely after clear evidence of suboptimal dila-
tations. A single stent of 12 or 14 mm in diameter  40
mm in length was deployed in 13 patients. In one patient,
two (overlapping) stents (one 14 mm  40 mm and one
12  20 mm) were used in the same session. All but one
were released at the distal segment of the AZ arch where
a severe twisting of the vein was present. In one patient,
a 12-mm  40-mm stent was implanted at the vein ostium
(Fig 3, a-c). Four patients presented with a left innominate
vein hypoplasia with evidence of blood ﬂow drainage into
the right atrium through a left persistent superior vena
cava and the coronary sinus. Selective catheterization of
the left IJV was then carried out through the coronary
sinus and the left persistent superior vena cava as previously
reported by our group.22 Two patients underwent inadver-
tent catheterization of the left common femoral artery;
percutaneous closure devices were used without further
sequelae. Out of 1199 patients, 1177 (98.2%) were dis-
charged at 4 hours from the intervention. Nineteen
(1.6%) patients were discharged the following day, whereas
three (0.3%) patients were discharged at 2 days, 3 days, and
7 days, respectively. Follow-up with CDS was completed at
2, 6, and 12 months by 1141 out of 1199 (95.2%), 1024out of 1129 (90.7%), and 874 out of 1026 (85.2%)
patients, respectively. The overall rate of CSSVI, regarded
as either persistence or recurrence of $two Zamboni
criteria following percutaneous transluminal angioplasty,
was 11.8% at 6 months and 19.1% at 1 year, respectively.
Primary end points. Major complications included
one (0.1%) AZ rupture occurring during a standard
balloon dilatation with a 10-  20-mm high-pressure
balloon. The patient had sudden unexpected severe
hypotension requiring blood transfusion and vital
parameters stabilization. Selective phlebography showed
a 2-cm vein pseudoaneurysm close to the AZ ostium
causing severe bleeding in the mediastinum. A self-
expandable bare stent was promptly deployed (EverFlex;
eV3, Plymouth, Minn) at the origin of the AZ followed
by coil embolization of the sac. Indeed, a 4F Cobra
catheter was advanced through the meshes of the stent,
and three 4  4 ﬁbered coils (Vortex; Boston Scientiﬁc,
Natick, Mass) were carefully packed within the lesion
(Fig 3). The patient did well and was discharged after 7
days. There were two (0.2%) balloon deﬂagrations, both
occurring during a prolonged dilatation for a very though
stenosis in the left IJV. Both devices were high-resistance
balloons of 18  20 mm. Unfortunately, it was not
possible to remove them through the 10F introducer
sheath in the left groin. Both patients were treated in the
cath lab at the time of the endovascular intervention by
surgical opening of the left common femoral vein. After
careful removal of all the fragments, vein suturing was
obtained; the endovascular intervention was then
continued in the standard fashion with no evidence of
further complications. Both patients were discharged
home the following day in good general conditions. One
Fig 3. Azygos vein (AZ) rupture following balloon angioplasty at the vein outlet. Subtraction angiography shows
massive extravasation of contrast medium (arrows) within the mediastinum (a). A standard balloon is placed close to the
vein outlet and inﬂated at two atmospheres for 20 minutes in an effort to stop the vessel from bleeding (b). After
balloon removal, complete cessation of bleeding is noted. However, a 3-  3-cm pseudoaneurysm of the AZ (arrow)
located at 2 cm from the junction with the superior vena cava is also seen (c). Bare stent placement of the AZ (d)
followed by coil embolization of the pseudoaneurysm. Coil embolization was performed using a 4F Cobra catheter
with its tip advanced through the meshes of the stent (e). Conﬁrmation angiography shows good coil packaging of the
sac with a preserved ﬂow throughout the AZ. A vein spasm of the descending portion of the AZ is noted at the end of
the procedure (arrows) (f). SVC, Superior vena cava.
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ization was reported. It was caused by occurrence of
a vein wall tear, likely due to a traumatic introducer sheath
advancement following a difﬁcult left CFV puncture. The
patient was readmitted 3 days after the discharge and
successfully treated by open surgery. Three patients
(0.3%) were found to have thrombosis in the left IJV
within 30 days from the percutaneous transluminal
angioplasty. They were readmitted due to occurrence of
sudden pain in the neck. All thromboses were discovered
at CDS obtained at 17, 19, and 23 days. The overall rate
of major complications at 30 days was as low as 0.6% (7 of
1219). Of importance was that all major complications
occurred during the ﬁrst 400 cases treated (Table III).
Procedural success was obtained in 1192 patients (99.2%)
and 1212 (99.2 %) procedures. In fact, selective study of
all target vessels was not possible in three (0.3%) and
seven (0.6%) cases due to a vein agenesis (one left IJV and
two AZ vein) and complete occlusion/thrombosis (tworight and left IJVs) following previous endovascular
balloon dilatations, respectively. Technical success of the
IJV was obtained in 1084 (90.4%) patients and 1104
(90.6%) procedures. Speciﬁcally, in 81 (6.8%) patients,
a persistent stenosis >50% of at least one IJV was seen
at conﬁrmation phlebography. In all these patients,
signiﬁcant external compression (due to presence of sur-
rounding structures such as muscles, carotid artery, or
bones compressing the IJV at one or more vein sites) not
responding to repeat and prolonged balloon dilatation
was noted. Seven (0.6%) patients showed a residual
stenosis >50% following percutaneous transluminal
angioplasty, either at the vein outlet (three patients; two
left and one right IJV) or in the distal portion (four
patients; three left and one right IJV), whereas 17 (1.4%)
showed persistent abnormal ﬂow (ﬁve in the right and 12
in the left side). Finally, in the 10 (0.8%) patients pre-
senting with agenesis or total occlusion of one target
vessel, although the remaining target vessels were dilated
Table IV. Primary and secondary end points calculated at 30 days in a total of 1219 endovascular treatments
Adverse events Total, No. (%) 0-400, No. (%) 401-1219, No. (%)
Primary end points
Major complications
Death -
Stroke -
Myocardial infarction -
Postprocedural venous thrombosis 3 (0.2) 3 (0.2) -
Severe bleeding in the groin requiring open surgery 1 (0.1) 1 (0.1) -
Vessel rupture requiring blood transfusion 1 (0.1) 1 (0.1) -
Surgical opening of common femoral vein to remove balloon fragments 2 (0.2) 2 (0.2) -
Total 7 (0.6) 7 (0.6) -
Unsuccessful catheterization of all target vessels
AZ 2 (0.2) 2 (0.2) -
IJV 8 (0.7) 2 (0.2) 6 (0.5)
Procedural success 1209 (99.2) 396 (99) 813 (99.2)
Secondary end points
Minor complications
Mild contrast reaction 3 (0.2) 2 (0.2) 1 (0.1)
Transient cardiac arrhythmia 13 (1.1) 8 (0.7) 5 (0.4)
Puncture site bleeding or groin hematoma 10 (0.8) 7 (0.6) 3 (0.3)
Neck hematoma 2 (0.2) 1 (0.1) 1 (0.1)
Lung migration of a balloon fragment 1 (0.1) 1 (0.1) -
Hemotimpanus 1 (0.1) 1 (0.1) -
Common femoral artery pseudoaneurysm 1 (0.1) 1 (0.1) -
Total 31 (2.5) 21 (1.7) 10 (0.8)
AZ, Azygos vein; IJV, internal jugular vein.
Complications have also been calculated before and after the ﬁrst 400 procedures performed.
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the brain or spinal cord to the heart could not be
obtained.
Successful recanalization of the AZ was obtained in
911 (97.4%) out of 935 patients and 934 (97.4%) out of
958 procedures.
Secondary end points. A transient cardiac arrhythmia
was reported in 13 (1.1%) cases. In four procedures, the
tachyarrhythmias resolved within 2 hours, whereas in the
remaining nine, it progressed to atrial ﬁbrillation that
required a 24-hour hospitalization before discharge. Ten
(0.8%) slight bleeding or hematomas in the groin (seven
needing further hospital care <12 hours and three >12
hours) with no clinical consequences, two slight right neck
hematomas (0.2%) not requiring hospitalization, and one
(0.1%) hemo-tympanum on the 25th day after discharge
were also reported. In one (0.1%) patient, a fragment of
a ruptured balloon migrated from the left IJV to the right
pulmonary artery, thus requiring the use of a dedicated
snare catheter (GoosNeck snare catheter; eV3) to retrieve
it from the lung into the 10F introducer sheath. Finally,
three (0.3%) mild contrast reactions occurred. All of them
became evident within 2 hours from the endovascular
intervention and were treated with antihistamine and
intravenous ﬂuid administration. One (0.1%) patient was
readmitted at 3 days with signs of moderate hemoglobin
depletion. The patient underwent computed tomography
scan that showed a 1.2-  1.8-mm left common femoral
artery pseudoaneurysm, which was promptly excluded by
coil embolization. At 30-day follow-up, the rate of minorcomplications was 2.5% (31 of 1219 procedures), whereas
the overall rate of complications was 3.1% (38 of 1219
procedures; Table IV).
DISCUSSION
The present study was not intended to evaluate clinical
outcomes of angioplasty in CCSVI patients but was
focused on straight evaluation of the intraprocedural and
short-term risks associated with this intervention. In our
experience of more than 1200 patients performed over
the course of 2 years, the rate of minor and major compli-
cations was in accord with those published so far in the
literature.25-29,32-36 No major contrast medium-related
complications occurred. There was one AZ rupture leading
to a massive bleeding within the mediastinum (Fig 3),
whereas no severe bleedings from the IJVs were seen
following percutaneous transluminal angioplasty. Indeed,
in certain cases, it was possible to observe in the AZ
and/or in the IJVs a slight bleeding after angioplasty
with a small amount of contrast coming out and
surrounding the vessels just at the site of ballooning. In
fact, in a few patients, mostly those <25 years old, vein
malformations at the vessel outlet have shown to be partic-
ularly resistant to balloon dilation, thus requiring multiple
attempts at ballooning as well as a higher pressure of
balloon inﬂation. In case of an inﬂation pressure greater
than 28 and 22 atmospheres in 12- to 18-mm and 20- to
26-mm-diameter balloons, respectively, a tear in the vessel
wall, as a result of sudden vein malformation disruption,
may occur. Fortunately, in such a scenario, the low pressure
Fig 4. The proximal segment of the azygos vein (AZ), which is the portion between the vena cava and the azygous
arch (within the circle), may lead to a massive bleeding into the mediastinum if it breaks during balloon dilatation
(a and b). SVC, Superior vena cava.
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lar tissue surrounding both the IJV and the distal part of
the AZ (arch and descending portion) prevent the blood
from extravasating into the neighboring tissues (in rare
cases, a limited amount of blood may slightly leak from
the site of balloon dilatation with no clinical conse-
quences). Nevertheless, the proximal segment of the AZ,
which is the portion of the vein arising from the superior
vena cava and extending up to the AZ arch, is not sur-
rounded by any tissue37; if not promptly recognized,
a rupture of the AZ or even a simple tear at this level
following angioplasty is likely to lead to a massive bleeding
into the mediastinum with subsequent risk of ipovolemic
shock (Fig 4). In order to stop the vein from bleeding,
the use of a stent, to be placed at the AZ origin, may be
highly required. In our case, we released a bare stent at
the site of bleeding followed by deployment of several
ﬁbered coils through the stent meshes. The use of a covered
stent without the need of placing the coils would have been
faster and easier, but it would have probably been at
increased risk of thrombosis or in-stent restenosis in the
long term. Moreover, no evidence of covered stent implan-
tation in the AZ territory has been ever reported in the
literature up to now. For this reason also, we preferred to
avoid using a covered prosthesis in the AZ.
A very dreadful complication was the postangioplasty
vein thrombosis, which accounted for a total of three cases;
importantly, all of them occurred in the ﬁrst 112 patients
treated.
However, since we prolonged the time of heparin
administration from 15 to 40 days, such a complication
was no longer seen. Iatrogenic cardiac arrhythmia (fol-
lowed by atrial ﬁbrillation in nine cases) was the most
common complication in our series. Potential iatrogenic
causes of atrial ﬁbrillation include cardiac and non-
cardiac surgery and administration of a variety of medica-
tions including bronchodilating beta-agonists, variousnonprescription cold remedies, antihistamines, local ane-
sthetics, and caffeine-containing beverages.38 In our
series, all cardiac arrhytmias developed during guide-
wire/catheter passage from the inferior to superior
vena cava or at the time of balloon dilatation of the
AZ. The presence of atrial ﬁbrillation contributes to
morbidity and mortality under a variety of circumstances.
Thus, a rapid ventricular response secondary to the pres-
ence of atrial ﬁbrillation can produce myocardial ischemia
with resultant unstable angina or even myocardial infarc-
tion in a patient with underlying arteriosclerotic coronary
artery disease.39,40 Considerable attention should be
focused on patients with history of myocardial infarction
and/or congestive heart failure who undergo venous
angioplasty for CCSVI. Another relatively common
complication was the occurrence of bleeding and/or
hematomas at the access site. It was mostly seen in those
patients who discontinued bed rest due to rapid postop-
erative recovery of their walking capability. However, it
is not possible to exclude that an inadvertent puncture
of the arterial bed might have occurred during the
attempts at femoral vein puncture, particularly in those
cases where puncturing proved to be extremely difﬁcult.
Indeed, a main limitation of the present series is that no
CDS evaluation of the venous access was obtained
before femoral vein puncture. Actually, a proper pre-
evaluation of the target vessel with CDS has been re-
ported to reduce the rate of complications at the entry
site.41,42CONCLUSIONS
Our study, which is the largest interventional one ever
carried out in such a population, conﬁrms that the rate of
adverse events following catheter angioplasty is reasonably
low with low risk of serious adverse events. However,
a proper learning curve seems to highly reduce the rate
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 6 Lupattelli et al 1617of complications. In our experience, the vast majority of
complications occurred in the ﬁrst 400 cases performed.
AUTHOR CONTRIBUTIONS
Conception and design: TL, PO
Analysis and interpretation: TL, GB, ER
Data collection: GB, ER, VD, IF, RF
Writing the article: TL
Critical revision of the article: TL, FG
Final approval of the article: TL, PO
Statistical analysis: IF, ER
Obtained funding: TL, PO
Overall responsibility: TL
REFERENCES
1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and
its pathogenesis. N Engl J Med 2006;354:942-55.
2. Barnet MH, Sutton I. the pathology of multiple sclerosis: a paradigm
shift. Curr Opin Neurol 2006;19:242-7.
3. Zamboni P. The big idea: iron-dependent inﬂammation in venous
disease and proposed parallels in multiple sclerosis. J R Soc Med
2006;99:589-93.
4. Zamboni P, Lanzara S, Mascoli F, Caggiati A, Liboni A. Inﬂammation
in venous disease. Int Angiol 2008;27:361-9.
5. Zivadinov R, Galeotti R, Hojnacki D, Menegatti E, Dwyer MG,
Schirda C, et al. Value of MR venography for detection of internal
jugular vein anomalies in multiple sclerosis: a pilot longitudinal study.
Am J Neurorad 2011;32:938-46.
6. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G,
Dall’Ara S, et al. Chronic cerebrospinal venous insufﬁciency in patients
with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:392-9.
7. Singh AV, Zamboni P. Anomalous venous blood ﬂow and iron
deposition in multiple sclerosis. J Cereb Blood Flow Metab 2009;29:
1867-78.
8. Lee BB, Choe YH, Ahn JM, Do YS, Kim DI, Huh SH, et al. The new
role of MRI (Magnetic Resonance Imaging) in the contemporary
diagnosis of venous malformation: can it replace angiography? J Am
Coll Surg 2004;198:549-58.
9. Schreiber SJ, Lurtzing F, Gotze R, Doepp F, Klingebiel R,
Valdueza JM. Extrajugular pathways of human cerebral venous blood
drainage assessed by duplex ultrasound. J Appl Physiol 2003;94:
1802-5.
10. Zamboni P, Menegatti E, Galeotti R, Malagoni AM, Tacconi G,
Dall’Ara S, et al. The value of cerebral Doppler venous haemodynamics
in the assessment of multiple sclerosis. J Neurol Sci 2009;282:21-7.
11. Zaniewski M, Kostecki J, Ziaja K, Urbanek T, Kuczmik W,
Krzystanek E, et al. Endovascular surgery for the treatment of symp-
toms of multiple sclerosis. Preliminary report. Chirurgia Polska
2010;12:12-7.
12. Zamboni P, Menegatti E, Bartolomei I, Galeotti R, Malagoni AM,
Tacconi G, et al. Intracranial venous haemodynamics in multiple scle-
rosis. Curr Neurovasc Res 2007;4:252-8.
13. Zamboni P, Consorti G, Galeotti R, Gianesini S, Menegatti E,
Tacconi G, et al. Venous collateral circulation of the extracranial
cerebrospinal outﬂow routes. Curr Neurovasc Res 2009;6:204-12.
14. Bartolomei I, Salvi F, Galeotti R, Salviato E, Alcanterini M,
Menegatti E, et al. Hemodynamic pattern of chronic cerebrospinal
venous insufﬁciency in multiple sclerosis. Correlation with symptoms at
onset and clinical course. Int Angiol 2010;29:183-8.
15. Sundström P, Wåhlin A, Ambarki K, Birgander R, Eklund A, Malm J.
Venous and cerebrospinal ﬂuid ﬂow in multiple sclerosis: a case-control
study. Ann Neurol 2010;68:255-9.
16. Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ. No cere-
brocervical venous congestion in patients with multiple sclerosis. Ann
Neurol 2010;68:173-83.17. Centonze D, Floris R, Stefanini M, Rossi S, Fabiano S, Castelli M,
et al. Proposed chronic cerebrospinal venous insufﬁciency criteria do
not predict multiple sclerosis risk or severity. Ann Neurol 2011;70:
52-9.
18. Baracchini C, Perini P, Calabrese M, Causin F, Rinaldi F, Gallo P. No
evidence of chronic cerebrospinal venous insufﬁciency at multiple
sclerosis onset. Ann Neurol 2011;69:90-9.
19. Floris R, Centonze D, Fabiano S, Stefanini M, Marziali S, Del
Giudice C, et al. Prevalence study of chronic cerebrospinal venous
insufﬁciency in patients with multiple sclerosis: preliminary data. Radiol
Med 2012;117:855-64.
20. Garaci FG, Marziali S, Meschini A, Fornari M, Rossi S, Melis M, et al.
Brain hemodynamic changes associated with chronic cerebrospinal
venous insufﬁciency are not speciﬁc to multiple sclerosis and do not
increase its severity. Radiology 2012;265:233-9.
21. Menegatti E, Genova V, Tessari M, Malagoni AM, Bartolomei I,
Zuolo M, et al. The reproducibility of colour Doppler in chronic
cerebrospinal venous insufﬁciency associated with multiple sclerosis. Int
Angiol 2010;29:121-6.
22. Zamboni P. Regarding “no cerebrocervical venous congestion in
patients with multiple sclerosis. Intraluminal jugular septation”. Ann
Neurol 2010;68:969; author reply: 970.
23. Zamboni P, Morovic S, Menegatti E, Viselner G, Nicolaides AN.
Screening for chronic cerebrospinal venous insufﬁciency (CCSVI)
using ultrasound - recommendations for a protocol. Int Angiology
2011;30:571-97.
24. Lupattelli T, Benassi F, Righi E, Bavera P, Bellagamba G. Percutaneous
transluminal angioplasty in a patient with chronic cerebrospinal venous
insufﬁciency and persistent left superior vena cava. Phlebology 2012
November 15; [Epublication ahead of print].
25. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Gianesini S,
Bartolomei I, et al. A prospective open-label study of endovascular
treatment of chronic cerebrospinal venous insufﬁciency. J Vasc Surg
2009;50:1348-58.
26. Zamboni P, Galeotti R, Weinstock-Guttman B, Kennedy C,
Salvi F, Zivadinov R. Venous angioplasty in patients with multiple
sclerosis: results of a pilot study. Eur J Vasc Endovasc Surg
2012;43:116-22.
27. Ludyga T, Kazibudzki M, Simka M, Hartel M, Swierad M,
Piegza J, et al. Endovascular treatment for chronic cerebrospinal
venous insufﬁciency: is the procedure safe? Phlebology 2010;25:
286-95.
28. Mandato KD, Hegener PF, Siskin GP, Haskal ZJ, Englander MJ,
Garla S, et al. Safety of endovascular treatment of chronic cerebrospinal
venous insufﬁciency: a report of 240 patients with multiple sclerosis.
J Vasc Interv Radiol 2012;23:55-9.
29. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M,
et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the
McDonald criteria. Ann Neurol 2011;69:292-302.
30. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A prac-
tical method for grading the cognitive state of patients for the clinician.
J Psychiatr Res 1975;12:189-98.
31. Kurtzke JF. Disability rating scales in multiple sclerosis. Ann N Y Acad
Sci 1984;436:347-60.
32. Petrov I, Grozdinski L, Kaninski G, Iliev N, Iloska M, Radev A. Safety
proﬁle of endovascular treatment for chronic cerebrospinal venous
insufﬁciency in patients with multiple sclerosis. J Endovasc Ther
2011;18:314-23.
33. Malagoni AM, Galeotti R, Menegatti E, Manfredini F, Basaglia N,
Salvi F, et al. Is chronic fatigue the symptom of venous insufﬁciency
associated with multiple sclerosis? A longitudinal pilot study. Int Angiol
2010;29:176-82.
34. Siskin GP, Haskal ZJ, McLennan G, Dake MD, Haacke EM,
McDonald S, et al. Development of a research agenda for evaluation of
interventional therapies for chronic cerebrospinal venous insufﬁciency:
proceedings from a multidisciplinary research consensus panel. J Vasc
Interv Radiol 2011;22:587-93.
35. Zamboni P, Bertolotto A, Boldrini P, Cenni P, D’Alessandro R,
D’Amico R, et al. Efﬁcacy and safety of venous angioplasty of the
extracranial veins for multiple sclerosis. Brave Dreams Study (Brain
JOURNAL OF VASCULAR SURGERY
1618 Lupattelli et al December 2013Venous Drainage Exploited Against Multiple Sclerosis): study protocol
for a randomized controlled trial. Trials 2012;13:183.
36. Vedantham S, Benenati JF, Kundu S, Black CM, Murphy KJ,
Cardella JF, et al. Interventional endovascular management of chronic
cerebrospinal venous insufﬁciency in patients with multiple sclerosis:
a position statement by the Society of Interventional Radiology,
endorsed by the Canadian Interventional Radiology Association. J Vasc
Interv Radiol 2010;21:1335-7.
37. Smathers RL, Buschi AJ, Pope TL Jr, Brenbridge AN, Williamson BR.
The azygous arch: normal and pathologic CT appearance. AJR Am J
Roentgenol 1982;139:477-83.
38. Mackstaller LL, Alpert JS. Atrial ﬁbrillation: a review of mechanism,
etiology, and therapy. Clin Cardiol 1997;20:640-50.
39. Crijns HJ, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder IC, van
den Berg MP, et al. Prognostic value of the presence and developmentof atrial ﬁbrillation in patients with advanced chronic heart failure. Eur
Heart J 2000;21:1238-45.
40. Behar S, Tanne D, Zion M, Reicher-Reiss H, Kaplinsky E, Caspi A,
et al. Incidence and prognostic signiﬁcance of chronic atrial ﬁbrillation
among 5839 consecutive patients with acute myocardial infarction. Am
J Cardiol 1992;70:816-8.
41. PrabhuMV, Juneja D, Gopal PB, SathyanarayananM, Subhramanyam S,
Gandhe S, et al. Ultrasound-guided femoral dialysis access placement:
a single-center randomized trial. Clin J Am Soc Nephrol 2010;5:235-9.
42. Chen JY, Chang KC, Lin YC, Chou HT, Hung JS. Feasibility and
accuracy of pre-procedure imaging of the proximal cephalic vein by
duplex ultrasonography in pacemaker and deﬁbrillator implantation.
J Interv Card Electrophysiol 2004;10:31-5.
Submitted Jan 8, 2013; accepted May 28, 2013.
